Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All convalescent plasma..
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchConvalescent PlasmaConv. Plasma (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes    Recent:   
0 0.5 1 1.5 2+ Mortality, day 28 -38% Improvement Relative Risk Mortality, day 14 -100% Improvement -11% Hospitalization time -67% Conv. Plasma  PLACOVID  LATE TREATMENT  RCT Is late treatment with convalescent plasma beneficial for COVID-19? RCT 160 patients in Brazil (July - December 2020) Higher mortality with convalescent plasma (not stat. sig., p=0.42) c19early.org Sekine et al., European Respiratory J., Jul 2021 Favors conv. plasma Favors control

Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial

Sekine et al., European Respiratory Journal, doi:10.1183/13993003.01471-2021, PLACOVID, NCT04547660
Jul 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
RCT 160 hospitalized patients in Brazil, showing no significant difference in outcomes with convalescent plasma.
risk of death, 38.5% higher, RR 1.38, p = 0.42, treatment 18 of 80 (22.5%), control 13 of 80 (16.2%), day 28.
risk of death, 100% higher, RR 2.00, p = 0.28, treatment 10 of 80 (12.5%), control 5 of 80 (6.2%), day 14.
risk of no improvement, 10.7% higher, RR 1.11, p = 0.74, treatment 31 of 80 (38.8%), control 28 of 80 (35.0%), day 28.
hospitalization time, 66.7% higher, relative time 1.67, p = 0.87, treatment 80, control 80.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sekine et al., 8 Jul 2021, Randomized Controlled Trial, Brazil, peer-reviewed, 28 authors, study period 15 July, 2020 - 10 December, 2020, average treatment delay 10.0 days, trial NCT04547660 (history) (PLACOVID). Contact: azavascki@hcpa.edu.br, permissions@ersnet.org.
This PaperConv. PlasmaAll
Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial
Leo Sekine, Beatriz Arns, Bruna R Fabro, Murillo M Cipolatt, Rafael R G Machado, Edison L Durigon, Edino Parolo, José Augusto S Pellegrini, Marina V Viana, Patrícia Schwarz, Thiago C Lisboa, José Miguel S Dora, Julia P Portich, Alessandra A Paz, Lucia Silla, Almeri M Balsan, Felipe Da-Silva Schirmer, Juliana P M Franz, Luciana M Da-Silveira, Raquel C Breunig, Viviana Petersen, Monalisa Sosnoski, Nanci F Mesquita, Fabiana Caroline Z Volpato, Daniel Sganzerla, Maicon Falavigna, Regis G Rosa, Alexandre P Zavascki
European Respiratory Journal, doi:10.1183/13993003.01471-2021
In this open-label, randomised clinical trial, two infusions of convalescent plasma therapy plus standard of care compared to standard of care did not result in higher proportion of clinical improvement on day 28 in patients with severe COVID-19 https://bit.ly/2TXuB6S
References
Agarwal, Mukherjee, Kumar, Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial), BMJ
Casadevall, Pirofski, The convalescent sera option for containing COVID-19, J Clin Invest
Gottlieb, Nirula, Chen, Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial, JAMA
Horby, Estcourt, Peto, Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Lancet
Huang, Wang, Li, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Janiaud, Axfors, Schmitt, Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis, JAMA
Joyner, Bruno, Klassen, Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients, Mayo Clin Proc
Joyner, Carter, Senefeld, Convalescent plasma antibody levels and the risk of death from COVID-19, N Engl J Med
Li, Zhang, Hu, Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial, JAMA
Libster, Marc, Wappner, Early high-titer plasma therapy to prevent severe Covid-19 in older adults, N Engl J Med
Lundgren, Grund, Barkauskas, A neutralizing monoclonal antibody for hospitalized patients with COVID-19, N Engl J Med
Rosner, Fundamentals of Biostatistics
Simonovich, Pratx, Scibona, A randomized trial of convalescent plasma in Covid-19 severe pneumonia, N Engl J Med
Wendel, Kutner, Machado, Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: preliminary lessons from a voluntary convalescent donor program, Transfusion
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention, JAMA
{ 'DOI': '10.1183/13993003.01471-2021', 'ISSN': ['0903-1936', '1399-3003'], 'URL': 'http://dx.doi.org/10.1183/13993003.01471-2021', 'abstract': '<jats:sec><jats:title>Background</jats:title><jats:p>The effects of convalescent plasma (CP) ' 'therapy in hospitalised patients with coronavirus disease 2019 (COVID-19) remain uncertain. ' 'This study investigates the effect of CP on clinical improvement in these ' 'patients.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>This is an ' 'investigator-initiated, randomised, parallel arm, open-label, superiority clinical trial. ' 'Patients were randomly (1:1) assigned to two infusions of CP plus standard of care (SOC) or ' 'SOC alone. The primary outcome was the proportion of patients with clinical improvement ' '28\u2005days after ' 'enrolment.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>A total of ' '160 (80 in each arm) patients (66.3% critically ill, 33.7% severely ill) completed the trial. ' 'The median (interquartile range (IQR)) age was 60.5 (48–68)\u2005years; 58.1% were male and ' 'the median (IQR) time from symptom onset to randomisation was 10 (8–12) days. Neutralising ' 'antibody titres &gt;1:80 were present in 133 (83.1%) patients at baseline. The proportion of ' 'patients with clinical improvement on day 28 was 61.3% in the CP+SOC group and 65.0% in the ' 'SOC group (difference −3.7%, 95% CI −18.8–11.3%). The results were similar in the severe and ' 'critically ill subgroups. There was no significant difference between CP+SOC and SOC groups ' 'in pre-specified secondary outcomes, including 28-day mortality, days alive and free of ' 'respiratory support and duration of invasive ventilatory support. Inflammatory and other ' 'laboratory marker values on days 3, 7 and 14 were similar between ' 'groups.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>CP+SOC did ' 'not result in a higher proportion of clinical improvement on day 28 in hospitalised patients ' 'with COVID-19 compared to SOC alone.</jats:p></jats:sec>', 'alternative-id': ['10.1183/13993003.01471-2021'], 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-7140-4980', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Sekine', 'given': 'Leo', 'sequence': 'first'}, {'affiliation': [], 'family': 'Arns', 'given': 'Beatriz', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Fabro', 'given': 'Bruna R.', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Cipolatt', 'given': 'Murillo M.', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0001-6974-5092', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Machado', 'given': 'Rafael R.G.', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Durigon', 'given': 'Edison L.', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Parolo', 'given': 'Edino', 'sequence': 'additional'}, { 'affiliation': [], 'family': 'Pellegrini', 'given': 'José Augusto S.', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Viana', 'given': 'Marina V.', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Schwarz', 'given': 'Patrícia', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Lisboa', 'given': 'Thiago C.', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0003-3386-713X', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Dora', 'given': 'José Miguel S.', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Portich', 'given': 'Julia P.', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Paz', 'given': 'Alessandra A.', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Silla', 'given': 'Lucia', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Balsan', 'given': 'Almeri M.', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Schirmer', 'given': 'Felipe da-Silva', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Franz', 'given': 'Juliana P.M.', 'sequence': 'additional'}, {'affiliation': [], 'family': 'da-Silveira', 'given': 'Luciana M.', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Breunig', 'given': 'Raquel C.', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Petersen', 'given': 'Viviana', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Sosnoski', 'given': 'Monalisa', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Mesquita', 'given': 'Nanci F.', 'sequence': 'additional'}, { 'affiliation': [], 'family': 'Volpato', 'given': 'Fabiana Caroline Z.', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Sganzerla', 'given': 'Daniel', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Falavigna', 'given': 'Maicon', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Rosa', 'given': 'Regis G.', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0001-5331-4837', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Zavascki', 'given': 'Alexandre P.', 'sequence': 'additional'}], 'container-title': 'European Respiratory Journal', 'container-title-short': 'Eur Respir J', 'content-domain': {'crossmark-restriction': True, 'domain': ['ersjournals.com']}, 'created': {'date-parts': [[2021, 7, 8]], 'date-time': '2021-07-08T17:05:27Z', 'timestamp': 1625763927000}, 'deposited': { 'date-parts': [[2022, 2, 10]], 'date-time': '2022-02-10T09:30:23Z', 'timestamp': 1644485423000}, 'funder': [ { 'DOI': '10.13039/501100001807', 'award': ['2016/20045-7', '2020/06409-1'], 'doi-asserted-by': 'publisher', 'name': 'Fundação de Amparo à Pesquisa do Estado de São Paulo'}, {'name': 'Instituto Cultural Floresta'}, { 'DOI': '10.13039/501100004263', 'award': ['16/2551-0000242-8'], 'doi-asserted-by': 'publisher', 'name': 'Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul'}], 'indexed': {'date-parts': [[2023, 1, 14]], 'date-time': '2023-01-14T10:50:02Z', 'timestamp': 1673693402972}, 'is-referenced-by-count': 32, 'issue': '2', 'issued': {'date-parts': [[2021, 7, 8]]}, 'journal-issue': { 'issue': '2', 'published-online': {'date-parts': [[2022, 2, 10]]}, 'published-print': {'date-parts': [[2022, 2]]}}, 'language': 'en', 'license': [ { 'URL': 'http://creativecommons.org/licenses/by-nc/4.0/', 'content-version': 'vor', 'delay-in-days': 0, 'start': { 'date-parts': [[2021, 7, 8]], 'date-time': '2021-07-08T00:00:00Z', 'timestamp': 1625702400000}}], 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1183/13993003.01471-2021', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '81', 'original-title': [], 'page': '2101471', 'prefix': '10.1183', 'published': {'date-parts': [[2021, 7, 8]]}, 'published-online': {'date-parts': [[2021, 7, 8]]}, 'published-print': {'date-parts': [[2022, 2]]}, 'publisher': 'European Respiratory Society (ERS)', 'reference': [ { 'DOI': '10.1016/S0140-6736(20)30183-5', 'doi-asserted-by': 'publisher', 'key': '2022021001300718000_59.2.2101471.1'}, { 'DOI': '10.1001/jama.2020.2648', 'doi-asserted-by': 'publisher', 'key': '2022021001300718000_59.2.2101471.2'}, { 'DOI': '10.1172/JCI138003', 'article-title': 'The convalescent sera option for containing COVID-19', 'author': 'Casadevall', 'doi-asserted-by': 'crossref', 'first-page': '1545', 'journal-title': 'J Clin Invest', 'key': '2022021001300718000_59.2.2101471.3', 'volume': '130', 'year': '2020'}, { 'DOI': '10.1056/NEJMoa2031893', 'doi-asserted-by': 'publisher', 'key': '2022021001300718000_59.2.2101471.4'}, { 'DOI': '10.1016/j.mayocp.2020.06.028', 'article-title': 'Safety update: COVID-19 convalescent plasma in 20,000 hospitalized ' 'patients', 'author': 'Joyner', 'doi-asserted-by': 'crossref', 'first-page': '1888', 'journal-title': 'Mayo Clin Proc', 'key': '2022021001300718000_59.2.2101471.5', 'volume': '95', 'year': '2020'}, { 'DOI': '10.1001/jama.2020.1004', 'doi-asserted-by': 'publisher', 'key': '2022021001300718000_59.2.2101471.6'}, { 'DOI': '10.1136/bmj.m3939', 'doi-asserted-by': 'publisher', 'key': '2022021001300718000_59.2.2101471.7'}, { 'DOI': '10.1056/NEJMoa2031304', 'doi-asserted-by': 'publisher', 'key': '2022021001300718000_59.2.2101471.8'}, { 'DOI': '10.1016/s0140-6736(21)00897-7', 'doi-asserted-by': 'publisher', 'key': '2022021001300718000_59.2.2101471.9'}, { 'DOI': '10.1111/trf.16065', 'article-title': 'Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: ' 'preliminary lessons from a voluntary convalescent donor program', 'author': 'Wendel', 'doi-asserted-by': 'crossref', 'first-page': '2938', 'journal-title': 'Transfusion', 'key': '2022021001300718000_59.2.2101471.10', 'volume': '60', 'year': '2020'}, { 'key': '2022021001300718000_59.2.2101471.11', 'unstructured': 'Rosner B . Fundamentals of Biostatistics. 7th edn. Boston, Brooks/Cole, ' 'Cengage Learning, 2011.'}, { 'DOI': '10.1001/jama.2021.2747', 'article-title': 'Association of convalescent plasma treatment with clinical outcomes in ' 'patients with COVID-19: a systematic review and meta-analysis', 'author': 'Janiaud', 'doi-asserted-by': 'crossref', 'first-page': '1185', 'journal-title': 'JAMA', 'key': '2022021001300718000_59.2.2101471.12', 'volume': '325', 'year': '2021'}, { 'DOI': '10.1056/NEJMoa2033700', 'doi-asserted-by': 'publisher', 'key': '2022021001300718000_59.2.2101471.13'}, { 'DOI': '10.1001/jama.2021.0202', 'article-title': 'Effect of bamlanivimab as monotherapy or in combination with etesevimab ' 'on viral load in patients with mild to moderate COVID-19: a randomized ' 'clinical trial', 'author': 'Gottlieb', 'doi-asserted-by': 'crossref', 'first-page': '632', 'journal-title': 'JAMA', 'key': '2022021001300718000_59.2.2101471.14', 'volume': '325', 'year': '2021'}, { 'DOI': '10.1056/NEJMoa2033130', 'article-title': 'A neutralizing monoclonal antibody for hospitalized patients with ' 'COVID-19', 'author': 'Lundgren', 'doi-asserted-by': 'crossref', 'first-page': '905', 'journal-title': 'N Engl J Med', 'key': '2022021001300718000_59.2.2101471.15', 'volume': '384', 'year': '2021'}], 'reference-count': 15, 'references-count': 15, 'relation': {}, 'resource': {'primary': {'URL': 'http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01471-2021'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': ['Pulmonary and Respiratory Medicine'], 'subtitle': [], 'title': 'Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical ' 'trial', 'type': 'journal-article', 'update-policy': 'http://dx.doi.org/10.1183/ers-crossmark-policy', 'volume': '59'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit